Mortality risk from exposure to beryllium: exposure assessment and CO-morbidities

This federal Project Grant award of $841,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research performed by Exponent Inc. to assess mortality risk from exposure to the environmental contaminant beryllium and investigate associated co-morbidities. The award, effective September 30, 2023 through September 29, 2026, will fund Exponent's multi-year research project focused on exposure assessment and analysis of the health impacts of beryllium exposure. By leveraging its scientific and engineering expertise, Exponent will conduct activities such as data analysis, modeling, and testing to better understand the relationships between beryllium exposure and increased mortality risk. This research aims to inform the development of improved prevention and mitigation strategies for protecting military personnel and the broader public from the health hazards of beryllium.